A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the effect of MK0859 when administered alone and when in combination with atorvastatin in lowering Low Density Lipoprotein -Cholesterol (LDL-C) in Japanese patients with dyslipidemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Anacetrapib; Atorvastatin; Atorvastatin Calcium; Oxazolidinones

Criteria

Inclusion Criteria:

• Patient is male or female and between the ages of 20 and 75 years diagnosed with dyslipidemia

Exclusion Criteria:

• Patients has Coronary Heart Disease (CHD) or CHD-equivalent disease (except diabetes)

• Patients has uncontrolled diabetes

• Patient is currently participating or has participated in a study with an investigational compound within the last 3 months